Karbapenem dirençli Klebsiella Pneumoniae kan dolaşım yolu enfeksiyonlarında risk faktörü ve mortalite; Türkiye’den bir üçüncü basamak hastane deneyimi

Yıl 2024, Cilt: 38 Sayı: 3, 273 - 280, 27.12.2024

Tuba Tatlı Kış , Yıldız Tezel , Feride Tamay Tatlı , Süleyman Yıldırım , Can Biçmen , Cenk Kıraklı

https://doi.org/10.18614/deutip.1591209

Öz

AMAÇLAR: Klebsiella pneumoniae, en önemli çoklu ilaca dirençli mikroorganizmalardan biridir. Karbapenem dirençli Klebsiella pneumoniae'nin (CRKP) neden olduğu enfeksiyonlar arasında, kan dolaşım yolu enfeksiyonları (KDYE) en yüksek ölüm oranına sahiptir. Bu çalışmanın amacı, sağlık bakımıyla ilişkili CRKP KDYE ile ilişkili risk faktörlerini, K. pneumoniae KDYE ölüm oranlarını ve yoğun bakım ünitesinde takip edilen hastalarda mortaliteyi etkileyen faktörleri değerlendirmektir.
YÖNTEMLER: Bu çalışma retrospektif bir vaka-kontrol çalışması olarak tasarlanmıştır. Hastalar karbapenem dirençlerine göre iki gruba ayrıldı; Grup 1: Kan kültürlerinde CRKP üremesi olan hastalar ve Grup 2: Kan kültürlerinde karbapenem duyarlı K. Pneumoniae (CSKP) üremesi olan hastalar. Gruplar arasında klinik ve demografik özellikler, 14 günlük ve tüm nedenlere bağlı mortalite oranları ve mortaliteyi etkileyen faktörler karşılaştırıldı. BULGULAR: CRKP grubunda daha yüksek vücut kitle indeksi, DM, COVID-19 nedeniyle yoğun bakıma yatış, daha önce karbapenem kullanımı, enfeksiyondan önce daha uzun süre yoğun bakımda kalma oranları CSKP grubuna kıyasla anlamlı derecede daha yüksekti. Çok değişkenli regresyon analizinde DM, COVID-19 nedeniyle yoğun bakıma yatış, daha önce karbapenem kullanımı, yoğun bakımda devamlı renal replasman tedavisi CRKP KDYE için risk faktörleriydi. Tüm nedenlere bağlı yoğun bakım ölümleri değerlendirildiğinde, yalnızca CRKP enfeksiyonunun yoğun bakım mortalitesi için bir risk faktörü olduğu bulundu.
SONUÇLAR: CRKP KDYE risk faktörlerinin tespiti önemlidir. Çalışmamızda CRKP KDYE varlığının yoğun bakımlarda mortalite için bağımsız bir risk faktörü olduğu bulundu.

Anahtar Kelimeler

bakteriyemi, karbapenem dirençli klebsiella pneumoniae, yoğun bakım ünitesi

Risk factors and mortality associatied with Carbapenem-resistant Klebsiella pneumoniae bloodstream infections; a tertiary hospital experience from Turkey

Öz

OBJECTIVES: Klebsiella pneumoniae is one of the most important multidrug-resistant microorganisms. Among the infections caused by Carbapenem-resistant Klebsiella pneumoniae (CRKP), bloodstream infections (BSI) have the highest mortality rate. The aim of this study was to evaluate the risk factors associated with healthcare-associated CRKP BSI, mortality rates of K. pneumoniae BSI and the factors affecting mortality in patients followed in the intensive care unit (ICU).
METHODS: This study was designed as a retrospective case-control study. Patients were divided into two groups according to their carbapenem resistance; Group 1: Patients with CRKP growth in blood cultures and Group 2: Patients with carbapenem sensitive K. Pneumoniae (CSKP) growth in blood cultures. Clinical and demographic characteristics, 14-day and all-cause mortality rates and factors affecting mortality were compared between the groups.
RESULTS: Rates of having higher body mass index, having DM, ICU admission due to COVID-19, prior use of carbapenems, a longer ICU stay before the infection were significantly higher in the CRKP group compared to CSKP group. In multivariate regression analysis having DM, ICU admission due to COVID-19, prior use of carbapenems, CRRT in the ICU were risk factors for CRKP BSI. When ICU deaths due to all causes are evaluated, only infection with CRKP was found to be a risk factor for ICU mortality.
CONCLUSIONS: Detection of CRKP BSI risk factors is important. In our study, the presence of CRKP BSI was found to be an independent risk factor for mortality in ICUs.

Anahtar Kelimeler

bloodstream infections, Carbapenem-resistant Klebsiella pneumoniae, intensive care unit

Kaynakça

• 1. Tacconelli E, Carrara E, Savoldi A, Harbarth S, Mendelson M, Monnet DL et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect Dis 2018;18(3):318–327.
• 2. Gomez-Simmonds, A. B. Nelson, D. Eiras, A. Loo, S. Jenkins, S. Whittier, et al. Combination regimens for treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother 2016;60:3601–3607.
• 3. Zhu WM, Yuan Z, Zhou HY. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection relative to two types of control patients: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2020;9(1):1–13.
• 4. WHO Regional Office for Europe; European Centre for Disease Prevention and Control. Antimicrobial Resistance Surveillance in Europe 2022–2020 Data; WHO Regional Office for Europe: Copenhagen, Denmark, 2022.
• 5. Centers for Disease Control and Prevention (U.S.). Antibiotic Resistance Threats in the United States, 2019; Centers for Disease Control and Prevention (U.S.): Atlanta, GA, USA, 2019.
• 6. WHO, Antimicrobial resistance surveillance in Europe 2023–2021 data. Available from https://www.who.int/europe/publications/i/item/9789289058537 date 28.07.2024.
• 7. Çölkesen F, Tarakçı A, Eroğlu E, Kacar F, Özdemir Armağan Ş, Can S, et al. Carbapenem-Resistant Klebsiella pneumoniae Infection and Its Risk Factors in Older Adult Patients. Clin Interv Aging. 2023 Jul 6;18:1037-1045.
• 8. Brennan BM, Coyle JR, Marchaim D, Pogue JM, Boehme M, Finks J, et al. Statewide surveillance of carbapenem-resistant enterobacteriaceae in Michigan. Infect Control Hosp Epidemiol. 2014;35:342–9.
• 9. Chen YC, Tsai IT, Lai CH, Lin KH, Hsu YC. Risk Factors and Outcomes of Community-Acquired Carbapenem-Resistant Klebsiella pneumoniae Infection in Elderly Patients. Antibiotics (Basel). 2024 Mar 20;13(3):282.
• 10. Zhu L, Liang L, Hui J, Lu J, Yang R, He Q, et al. Relationship between antibiotic exposure and carbapenem-resistant Klebsiella pneumoniae infection within four types of control patients: A systematic review and meta-analysis. J Glob Antimicrob Resist. 2023 Jun;33:137-151. doi: 10.1016/j.jgar.2023.02.020. Epub 2023 Mar 10.
• 11. Li J, Li Y, Song N, Chen Y. Risk factors for carbapenem-resistant Klebsiella pneumoniae infection: A meta-analysis. J Glob Antimicrob Resist. 2020 Jun;21:306-313.
• 12. Huang Y, Gong C, Fu J, Liu X, Bi H, Wang H, et al. Analysis of prognostic risk factors of bloodstream infection in intensive care unit patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2020 Dec;32(12):1440-1444.
• 13. Zhong L, Dong Z, Liu F, Li H, Tang K, Zheng C, et al. Incidence, clinical characteristics, risk factors and outcomes of patients with mixed Candida/bacterial bloodstream infections: a retrospective study. Ann Clin Microbiol Antimicrob. 2022 Nov 1;21(1):45.
• 14. Kuloglu TO, Unuvar GK, Cevahir F, Kilic AU, Alp E. Risk factors and mortality rates of carbapenem-resistant Gram-negative bacterial infections in intensive care units. J Intensive Med. 2024 Jan 9;4(3):347-354.
• 15. Micheli G, Sangiorgi F, Catania F, Chiuchiarelli M, Frondizi F, Taddei E, et al. The Hidden Cost of COVID-19: Focus on Antimicrobial Resistance in Bloodstream Infections. Microorganisms. 2023 May 16;11(5):1299.
• 16. Segala F.V, Pafundi P.C, Masciocchi C, Fiori B, Taddei E, Antenucci L, et al. Incidence of Bloodstream Infections Due to Multidrug-Resistant Pathogens in Ordinary Wards and Intensive Care Units before and during the COVID-19 Pandemic: A Real-Life, Retrospective Observational Study. Infection. 2023 Aug;51(4):1061-1069.
• 17. Lepape A, Machut A, Bretonnière C, Friggeri A, Vacheron C.H, Savey A. Effect of SARS-CoV-2 Infection and Pandemic Period on Healthcare-Associated Infections Acquired in Intensive Care Units. Clin. Clin Microbiol Infect. 2023 Apr;29(4):530-536.
• 18. Sinto R, Lie K.C, Setiati S, Suwarto S, Nelwan E.J, Djumaryo D.H, et al. Blood Culture Utilization and Epidemiology of Antimicrobial-Resistant Bloodstream Infections before and during the COVID-19 Pandemic in the Indonesian National Referral Hospital. Antimicrob Resist Infect Control. 2022 May 19;11(1):73.
• 19. Wang L, Zeng C, Li X, Li Y, Liu Z, Hu J. Mortality associated with carbapenem resistance in Klebsiella pneumoniae bloodstream infection: A propensity score-matched study. Infect Control Hosp Epidemiol. 2024 Mar 15:1-8.
• 20. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther. 2013 Oct;11(10):1053-63.
• 21. Chen Y, Chen Y, Liu P, Guo P, Wu Z, Peng Y, et al. Huang. Risk factors and mortality for elderly patients with bloodstream infection of carbapenem resistance Klebsiella pneumoniae: a 10-year longitudinal study. BMC Geriatr. 2022 Jul 13;22(1):573.